HeartSmart: Miniaturized heart tissue for high-throughput drug screening

Heart failure is a growing global burden, affecting more than 64 million people worldwide. One of the main bottlenecks in delivering effective treatments to cardiovascular disease (CVD) patients is the lack of predictive pre-clinical models that accurately resemble human (patho)physiology. At HeartSmart, our solution is a miniaturized heart tissue composed of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), cardiac fibroblasts (cFBs), and endothelial cells (ECs) for the unprecedented drug screening of heart failure compounds. We offer a complex human tissue model with increased throughput, ease-of-use, cost-effectiveness, and readout versatility, rendering us superior to competitors.